Status:

COMPLETED

Blood Pressure After PREeclampsia/HELLP by SELF Monitoring Study

Lead Sponsor:

Radboud University Medical Center

Collaborating Sponsors:

Interreg

Conditions:

Preeclampsia

Cardiovascular Risk Factor

Eligibility:

FEMALE

40-60 years

Phase:

NA

Brief Summary

RATIONALE: Women with a previous history of preeclampsia (PE)/HELLP have a twofold higher risk of cardiovascular disease (CVD) and a fourfold increased risk to develop hypertension at a relative youn...

Eligibility Criteria

Inclusion

  • previous preeclampsia/HELLP syndrome, defined as diastolic BP≥90 mmHg with proteinuria ≥ 0.3gram/24 h, during one or more pregnancies, more than 1 year ago.
  • 'early' or 'late' PE/HELLP
  • age ≥40 and ≤ 60 years

Exclusion

  • pregnant women or women wishing for future pregnancie(s)
  • inability to perform self BP measurements
  • not having a smartphone (Apple or Android)
  • already having regular hypertension control by GP or medical specialist
  • previous cardiovascular events, such as myocardial infarction , stroke, heart failure and symptomatic ischemic heart disease

Key Trial Info

Start Date :

July 13 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 30 2019

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT03228082

Start Date

July 13 2017

End Date

December 30 2019

Last Update

October 6 2020

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Katholisches Karl-Leisner-Klinikum GmbH

Kleve, Germany

2

Krankenhaus Bethanien

Moers, Germany

3

St. Josef Krankenhaus GmbH

Moers, Germany

4

Rijnstate Ziekenhuis

Arnhem, Netherlands